top of page

Leveraging ARV Optimization Opportunities to Unlock National Cost Savings

Updated: Dec 8, 2021


This memo highlights the benefits, market considerations, and potential for savings of three ARV optimization opportunities.

  1. Proactively switch eligible adult second-line patients on protease inhibitors to DTG-based regimens

  2. Ensure transition of pediatric patients to appropriate optimal products as they age and grow

  3. Move to larger, carton-less pack sizes to enable multi-month dispensing


Comentarios


  • LinkedIn
  • Facebook
  • Twitter
  • Instagram
  • YouTube

383 Dorchester Avenue, Suite 400

Boston, MA 02127

The goal of the HIV New Product Introduction Toolkit is to stimulate conversations between government, partners, and communities on new product introduction. Please feel free to share any thoughts, questions, or additional resources for consideration by contacting us via email at HIVToolkit@clintonhealthaccess.org.

 

© 2022  Clinton Health Access Initiative - Global HIV Access Program

bottom of page